Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
OPHT's Cash-to-Debt is ranked higher than
76% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. OPHT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OPHT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.24
OPHT's Equity-to-Asset is ranked lower than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OPHT: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
OPHT' s Equity-to-Asset Range Over the Past 10 Years
Min: -13.26  Med: 0.11 Max: 0.36
Current: 0.24
-13.26
0.36
Interest Coverage No Debt
OPHT's Interest Coverage is ranked higher than
69% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPHT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 0.16
Beneish M-Score: 4.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 25.92
OPHT's Operating Margin % is ranked lower than
82% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. OPHT: 25.92 )
Ranked among companies with meaningful Operating Margin % only.
OPHT' s Operating Margin % Range Over the Past 10 Years
Min: -384.14  Med: -239.84 Max: 25.92
Current: 25.92
-384.14
25.92
Net Margin % 26.69
OPHT's Net Margin % is ranked lower than
83% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. OPHT: 26.69 )
Ranked among companies with meaningful Net Margin % only.
OPHT' s Net Margin % Range Over the Past 10 Years
Min: -379.93  Med: -283.02 Max: 26.69
Current: 26.69
-379.93
26.69
ROA % 22.57
OPHT's ROA % is ranked lower than
72% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. OPHT: 22.57 )
Ranked among companies with meaningful ROA % only.
OPHT' s ROA % Range Over the Past 10 Years
Min: -241.11  Med: -49.53 Max: 22.57
Current: 22.57
-241.11
22.57
ROC (Joel Greenblatt) % 2302.69
OPHT's ROC (Joel Greenblatt) % is ranked lower than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. OPHT: 2302.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPHT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26895.89  Med: -12055.47 Max: 2302.69
Current: 2302.69
-26895.89
2302.69
3-Year EBITDA Growth Rate 1.40
OPHT's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. OPHT: 1.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OPHT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: -27.7 Max: 1.4
Current: 1.4
-44.4
1.4
3-Year EPS without NRI Growth Rate -4.90
OPHT's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. OPHT: -4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPHT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.3  Med: -41 Max: -4.9
Current: -4.9
-42.3
-4.9
GuruFocus has detected 2 Warning Signs with Ophthotech Corp OPHT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPHT's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

OPHT Guru Trades in Q4 2016

Paul Tudor Jones 67,023 sh (+844.78%)
Pioneer Investments Sold Out
Steven Cohen Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
Q1 2017

OPHT Guru Trades in Q1 2017

Jim Simons 1,858,300 sh (New)
Paul Tudor Jones 33,923 sh (-49.39%)
» More
Q2 2017

OPHT Guru Trades in Q2 2017

Steven Cohen 150,000 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 1,667,100 sh (-10.29%)
» More
Q3 2017

OPHT Guru Trades in Q3 2017

Jim Simons 2,060,600 sh (+23.60%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OPHT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BCLI, ROCO:6461, OSTO:ACTI, HKSE:08329, TSE:2342, XPAR:ONXEO, LSE:ABZA, TSX:TRIL, ROCO:1777, OTCPK:PRTX, NAS:AFMD, XBRU:BOTHE, LSE:VER, OSTO:IBT B, XPAR:GNRO, TPE:4133, OHEL:BIOBV, TSE:4583, NAS:ARQL, OTCPK:CYDY » details
Traded in other countries:O2T.Germany,
Headquarter Location:USA
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also engaged in developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. All the business activity of the group is functioned through the United States.

Top Ranked Articles about Ophthotech Corp

Quick Tips on Investing in the Pharmaceutical and Medical Device Industry An introduction to myself as well as a concise resource for new investors looking at better understanding the pharmaceutical and medical device world
Greetings GuruFocus Community, Read more...
INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Investors of Ophthotech Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ:OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/ophthotech or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices. On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29. Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ophthotech Corporation and Certain Officers – OPHT

NEW YORK, March 06, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ophthotech Corporation (“Ophthotech” or the “Company”) ( OPHT) and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of investors who purchased or otherwise acquired Caterpillar securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Ophthotech securities between May 11, 2015 and December 12, 2016, both dates inclusive, you have until March 13, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Ophthotech is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). AMD is a disorder of the central portion of the retina, which is responsible for central vision and color perception. The Company’s most advanced product candidate during the Class Period was Fovista, a PDGF aptamer. As a PDGF aptamer, Fovista was designed to block proteins that bind to cells on the outer lining of blood vessels. Fovista was to be administered in combination with VEGF agents, a standard of care for the treatment of wet AMD. Similar to PDGF aptamers, antiVEGF agents are designed to block proteins that bind to cells on the inner lining of blood vessels. By combining PDGF aptamers (like Fovista) and anti-VEGF agents, proteins on both the inner and outer lining of blood vessels which cause growth and leakage would be blocked, promoting blood vessel regression and reducing scarring. Prior to the Class Period, the Company had completed phase 1 and phase 2 studies evaluating Fovista in combination with the anti-VEGF Lucentis (ranibizumab), and had initiated multiple extension trials to evaluate Fovista in combination with other commercially available anti-VEGF agents. For instance, Ophthotech announced the results of its phase 2b clinical study of Fovista in combination with Lucentis on June 13, 2012, in a press release entitled “Anti-PDGF (1.5 mg) Combination Therapy Resulted in Additional 62% Increase in Visual Outcome Compared to Lucentis® Monotherapy.” The Phase 2b study was a prospective, randomized, controlled clinical trial of 449 patients with wet AMD, and a primary endpoint of mean vision gain. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The Complaint further alleges that these statements caused the Company stock to trade at artificially inflated prices. On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...
OPHTHOTECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ophthotech Corporation – (OPHT)

NEW ORLEANS, March 03, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Ophthotech Corporation (NASDAQ:OPHT), if they purchased the Company’s shares between May 11, 2015 and December 12, 2016, inclusive (the “Class Period”).  The action is pending in United States District Court for the Southern District of New York. 
What You May Do If you purchased shares of Ophthotech and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017. About the Lawsuit Ophthotech and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  The complaint alleges that Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint. On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. On this news, the price of Ophthotech’s shares plummeted. About Kahn Swick & Foti, LLC KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447

Read more...
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Ophthotech Corporation (OPHT) To Contact The Firm

STEVENSON, Md., March 03, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ophthotech Corporation (NASDAQ:OPHT) (“Ophthotech” or the “Company”) common stock during the period between May 11, 2015 and December 12, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Ophthotech common stock during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Ophthotech’s phase 3 clinical trials of Fovista would fail to achieve their primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone because Lucentis’ gain of vision in the Phase 2b clinical trial was not representative of Lucentis’ actual performance, Fovista’s gain of vision in the Phase 2b clinical trial was therefore biased, and Ophthotech inappropriately relied on its Phase 2b results as a means of touting its Phase 3 clinical trial of Fovista. According to the complaint, following a December 12, 2016 announcement that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis, the value of Ophthotech shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Ophthotech common stock purchased on or after May 11, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
Steven Cohen Adds to Fairmount Santrol, Ophthotech Guru increases his positions in energy company, biopharmaceutical company
Steven Cohen (Trades, Portfolio), founder and CEO of Point72 Asset Management, increased his position in two holdings recently. He increased his holding in Fairmount Santrol Holdings Inc. (NYSE:FMSA) by 21.2% on Dec. 7 and increased his position in Ophthotech Corp. (NASDAQ:OPHT) by 128.9% on Dec. 8. Read more...

Ratios

vs
industry
vs
history
PE Ratio 2.17
OPHT's PE Ratio is ranked lower than
99.99% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. OPHT: 2.17 )
Ranked among companies with meaningful PE Ratio only.
OPHT' s PE Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.6 Max: 3.02
Current: 2.17
1.45
3.02
PE Ratio without NRI 2.17
OPHT's PE Ratio without NRI is ranked lower than
99.99% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. OPHT: 2.17 )
Ranked among companies with meaningful PE Ratio without NRI only.
OPHT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.45  Med: 2.6 Max: 3.02
Current: 2.17
1.45
3.02
PB Ratio 2.72
OPHT's PB Ratio is ranked lower than
99.99% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OPHT: 2.72 )
Ranked among companies with meaningful PB Ratio only.
OPHT' s PB Ratio Range Over the Past 10 Years
Min: 1.86  Med: 15.82 Max: 157.45
Current: 2.72
1.86
157.45
PS Ratio 0.59
OPHT's PS Ratio is ranked higher than
54% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. OPHT: 0.59 )
Ranked among companies with meaningful PS Ratio only.
OPHT' s PS Ratio Range Over the Past 10 Years
Min: 0.38  Med: 28.7 Max: 70.25
Current: 0.59
0.38
70.25
EV-to-EBIT -1.04
OPHT's EV-to-EBIT is ranked higher than
93% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. OPHT: -1.04 )
Ranked among companies with meaningful EV-to-EBIT only.
OPHT' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.3  Med: -10.55 Max: 0.7
Current: -1.04
-37.3
0.7
EV-to-EBITDA -1.02
OPHT's EV-to-EBITDA is ranked higher than
94% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. OPHT: -1.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPHT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.7  Med: -10.55 Max: 0.7
Current: -1.02
-37.7
0.7
EV-to-Revenue -0.27
OPHT's EV-to-Revenue is ranked lower than
99.99% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. OPHT: -0.27 )
Ranked among companies with meaningful EV-to-Revenue only.
OPHT' s EV-to-Revenue Range Over the Past 10 Years
Min: -10.6  Med: 22.35 Max: 59.1
Current: -0.27
-10.6
59.1
Current Ratio 12.88
OPHT's Current Ratio is ranked higher than
72% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OPHT: 12.88 )
Ranked among companies with meaningful Current Ratio only.
OPHT' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 11.1 Max: 40.94
Current: 12.88
0.34
40.94
Quick Ratio 12.88
OPHT's Quick Ratio is ranked higher than
73% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. OPHT: 12.88 )
Ranked among companies with meaningful Quick Ratio only.
OPHT' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 11.1 Max: 40.94
Current: 12.88
0.34
40.94
Days Sales Outstanding 1.14
OPHT's Days Sales Outstanding is ranked higher than
83% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. OPHT: 1.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPHT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.14  Med: 25.32 Max: 31.1
Current: 1.14
1.14
31.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
OPHT's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. OPHT: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPHT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -190  Med: -189.4 Max: -4.4
Current: -4.4
-190
-4.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.94
OPHT's Price-to-Net-Cash is ranked lower than
99.99% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. OPHT: 2.94 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OPHT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.38  Med: 11.95 Max: 20.87
Current: 2.94
2.38
20.87
Price-to-Net-Current-Asset-Value 2.84
OPHT's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. OPHT: 2.84 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OPHT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.3  Med: 8.83 Max: 17.53
Current: 2.84
2.3
17.53
Price-to-Tangible-Book 2.75
OPHT's Price-to-Tangible-Book is ranked lower than
99.99% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. OPHT: 2.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OPHT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.22  Med: 11.22 Max: 125.07
Current: 2.75
2.22
125.07
Price-to-Median-PS-Value 0.02
OPHT's Price-to-Median-PS-Value is ranked higher than
88% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OPHT: 0.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPHT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.02 Max: 2.02
Current: 0.02
0.02
2.02
Price-to-Graham-Number 0.51
OPHT's Price-to-Graham-Number is ranked lower than
99.99% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. OPHT: 0.51 )
Ranked among companies with meaningful Price-to-Graham-Number only.
OPHT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.41  Med: 0.95 Max: 2.1
Current: 0.51
0.41
2.1
Earnings Yield (Greenblatt) % -93.95
OPHT's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. OPHT: -93.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPHT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.68  Med: -6.85 Max: 216.7
Current: -93.95
-95.68
216.7

More Statistics

Revenue (TTM) (Mil) $215.30
EPS (TTM) $ 1.57
Beta1.22
Short Percentage of Float3.95%
52-Week Range $2.24 - 40.34
Shares Outstanding (Mil)36.04

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $)
EPS ($) 2.90 -1.75 -1.45 -0.65
EPS without NRI ($) 2.90 -1.75 -1.45 -0.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}